MyOme and SickKids Partner to Validate DNA Methylation Signatures for Rare Disease Diagnosis

Rare disease diagnostics has long been defined by its limitations: long diagnostic odysseys, inconclusive variant interpretations, and patients who fall through the cracks of conventional sequencing-based approaches. A newly announced partnership between MyOme and the Hospital for Sick Children (SickKids) aims to close some of those gaps by validating DNA methylation signatures — also known as episignatures — as a clinically actionable layer of genomic evidence for rare disease testing.

The Technology

DNA methylation signatures represent a distinct class of biomarker derived from epigenomic data rather than the underlying DNA sequence itself. When certain genetic variants disrupt the machinery that regulates methylation patterns across the genome, the resulting aberrant signatures can serve as highly specific molecular fingerprints for particular conditions. This approach has gained traction in recent years as a way to reclassify variants of uncertain significance and confirm diagnoses that would otherwise remain elusive through standard variant-calling pipelines. MyOme, known for its computational genomics infrastructure, brings sequencing and informatics depth to the collaboration, while SickKids contributes one of the world's most established rare disease clinical programs and a substantial patient cohort against which these signatures can be rigorously evaluated.

Clinical Context

The validation effort is particularly significant given the diagnostic challenges inherent to rare disease medicine. Many patients with rare genetic conditions undergo years of testing before receiving a confirmed diagnosis, and a meaningful proportion never receive one at all. Variants of uncertain significance remain a persistent bottleneck: clinicians identify a potentially causative change in a gene but lack sufficient evidence to act on it clinically. Episignatures offer a complementary evidence stream that does not depend on sequence novelty alone. By demonstrating that a variant produces a characteristic and reproducible methylation pattern — one consistent with a known disorder — laboratories can move a case from ambiguous to resolved. SickKids is well positioned to provide the clinical validation framework this technology requires, given its volume of rare disease referrals and its experience translating experimental genomic methods into standard diagnostic workflows.

What's Next

The partnership will focus on building and validating the analytical and clinical evidence base needed to support broader adoption of methylation-based testing in rare disease diagnostic laboratories. Successfully clearing that bar would position episignature analysis as a routine adjunct to whole genome or whole exome sequencing rather than a research curiosity. Regulatory acceptance, reimbursement pathways, and laboratory standardization will all be essential milestones as this methodology matures. If the MyOme and SickKids collaboration produces the validation data the field needs, DNA methylation profiling could meaningfully expand the diagnostic yield for rare disease programs at clinical genomics centers worldwide, fundamentally reshaping what it means to deliver a complete genomic workup.